257 results on '"Neben K"'
Search Results
2. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma
3. Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure
4. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma
5. Akute Dyspnoe, subfebrile Temperaturen und Schüttelfrost bei einem Patienten mit multiplem Myelom
6. Strategien beim rezidivierten/refraktären multiplen Myelom
7. Strukturierte Diagnostik und internistische Therapie des CUP-Syndroms
8. CUP-Syndrom: Epidemiologie und Pathogenese
9. Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance
10. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
11. 1230P Elderly patients treated with afatinib in clinical practice: Final results of the GIDEON study in EGFR mutated NSCLC in Germany
12. Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation
13. Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma
14. ALLOGENEIC TRANSPLANTATION AFTER 8 GY TBI/CYCLOPHOSPHAMIDE CONDITIONING IN PATIENTS WITH ADVANCED MULTIPLE MYELOMA - A RETROSPECTIVE SINGLE CENTER ANALYSIS.: PH-P524
15. CUP-Syndrom: Molekulare Pathogenese und Biologie
16. Molekulare Pathogenese und Biologie des CUP-Syndroms
17. Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q
18. Correction:High-risk additional chromosomal abnormalities at low blast counts herald death by CML (Leukemia, (2020), 34, 8, (2074-2086), 10.1038/s41375-020-0826-9)
19. Centrosome aberrations as a possible mechanism for chromosomal instability in non-Hodgkin's lymphoma
20. Centrosome replication, genomic instability and cancer
21. Angiogenesis in hematologic malignancies
22. High-dose therapy with peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: long-term outcome and prognostic factors
23. Funktioelle Magnetresonanztomographie in Diagnostik und Therapiemonitoring beim Multiplen Myelom
24. Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma
25. Metascoring and gene expression profiling in multiple myeloma: V818
26. Evaluation of a novel class of sulfonanilides for targeted treatment of multiple myeloma: Dual-mechanism compounds inhibiting HIF1α-signaling and inducing apoptosis: V109
27. Proliferation and activation patterns of naïve, memory and regulatory T cells in patients with multiple myeloma during thalidomide, interferon-α and bortezomib maintenance therapy: V938
28. Inhibition of HIF1A signaling by a novel class of sulfonanilides for targeted treatment of multiple myeloma: V935
29. Rituximab maintenenance therapy in CD20+ B-cell Non-Hodgkin-Lymphoma - Final results of a multicenter prospective randomised phase II study: V683
30. Fluorescent in situ hybridization (FISH) for diagnosis and management of Multiple Myeloma: V40
31. Carcinoembryonic-antigen-related cell adhesion molecule (CEACAM) expression on multiple myelomas inhibits their recognition by autologous memory CD8 T cells: V808
32. Clinical outcome of patients with follicular lymphoma and bulky disease after Rituximab-CHOP immunochemotherapy with and without additional radiotherapy: V800
33. Proliferation Is a Central Independent Prognostic Factor and Target for Personalized and Risk Adapted Treatment in Multiple Myeloma: V644
34. Prognostic significance of whole body magnetic resonance imaging in 250 patients with asymptomatic monoclonal plasma cell disorders: V539
35. Combining chromosomal aberrations t(4;14), t(14;16) and del(17p13) with the ISS allows a stratification of myeloma patients into 3 prognostic groups after autologous stem cell transplantation: V295
36. Clinical Use of Gene Expression Based Risk Assessment and Identification of Possible Therapeutic Targets in Multiple Myeloma: V299
37. Staging of Monoclonal Plasma Cell Disease with Whole-body MRI: Comparison of the Durie and Salmonand the Durie and Salmon PLUS staging system: V294
38. Aurora-Kinase Inhibition for Tailored Risk-Adapted Treatment of Multiple Myeloma: B033
39. Whole-Body MRI in Asymptomatic Plasma Cell Disease: A018
40. Combination therapy of Thalidomide and Peginterferon in patients with progressive multiple myeloma
41. A man with hereditary exostoses and high-grade non-Hodgkin's lymphoma of the bone
42. Gene expression patterns in ependymoma correlate with tumor location and patient age: P981
43. Centrosome aberrations strongly correlate with cytogenetic risk profile and survival in B-cell chronic lymphocytic leukemia: P831
44. Thalidomide and CED chemotherapy followed by stem cell transplantation for poor prognosis multiple myeloma: P720
45. Distinct gene expression patterns in acute myeloid leukemia with normal karyotype characterized by FLT3 and RAS mutations: P601
46. Gene expression patterns in acute myeloid leukemia correlate with centrosome aberrations and numerical chromosome changes: P596
47. Identification of novel prognostic markers in medulloblas toma by gene expression experiments: V352
48. Mutations of the FLT3 and MLL genes in Acute Myeloid Leukemia (AML) with normal karyotype are associated with different gene expression patterns: 926
49. Polymorphisms of the interleukin-10 gene promoter in multiple myeloma: Thalidomide improves the outcome in patients carrying the high producer haplotype: 763
50. Low incidence of deep vein thrombosis in poor prognosis multiple myeloma patients treated with thalidomide and CED chemotherapy: 762
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.